Study offers new treatment options for high risk smoldering multiple myeloma
227 views · Published 5 December 2018 · 1:46 · Indexed 2 October 2026
Channel: Dana-Farber Cancer Institute · 2018 · Science & Technology
Mark Bustoros, MD shares results of the phase 2 study treating patients with high risk smoldering multiple myeloma with ixazomib, lenalidomide, and dexamethasone. Results of this study were presented at the 2018 ASH Annual Meeting and offer an early intervention option for patients with high risk smoldering multiple myeloma. For more information on our Center for Prevention of Progression: https://www.dana-farber.org/research/departments-centers-and-labs/departments-and-centers/center-for-prevention-of-progression-of-blood-cancers/
More from this channel
-
0:18
Importance of Joining the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:20
How to Join the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:18
How to Register as a Stem Cell Donor | Dana-Farber Cancer Institute
-
3:03
Sportscaster Jim Britt for the Jimmy Fund | Dana-Farber Cancer Institute
-
0:07
Dana-Farber Banners | Dana-Farber Cancer Institute
-
2:08
Barbers for the Jimmy Fund | Dana-Farber Cancer Institute
-
1:43
Pets | Dana-Farber Cancer Institute
-
1:34
Healthy Eating for the Holiday Season | Dana-Farber Cancer Institute